Dezima Pharma Completes Patient Enrolment for TULIP Phase 2b Study with CETP Inhibitor TA-8995
Next study to investigate effects on isolated, elevated Lp(a) to start early 2014

Naarden, The Netherlands, 13 January 2014 - Dezima Pharma ('Dezima'), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the completed enrolment of its phase 2b TULIP study. The aim of the study is to investigate the effects of TA-8995 (DEZ-001), a potential best-in-class CETP inhibitor, in around 360 patients with mild dyslipidemia on a wide range of plasma lipids, lipoproteins and validated biomarkers of cardiovascular disease (CVD).

read more